Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Darolutamide + EIS-12656 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Darolutamide | Nubeqa | BAY1841788|ODM-201 | Hormone - Anti-androgens 59 | Nubeqa (darolutamide) is an androgen receptor antagonist that binds to and prevents nuclear translocation of the androgen receptor, thereby inhibiting expression of genes downstream of androgen receptor signaling that regulate proliferation of prostate cancer cells (PMID: 28490267). Nubeqa (darolutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer, and as monotherapy or in combination with docetaxel in patients with metastatic hormone-sensitive prostate cancer (FDA.gov). |
| EIS-12656 | EIS12656|EIS 12656 | EIS-12656 inhibits CHD1L (ALC1), which potentially results in decreased PARP-mediated DNA damage repair and tumor cell apoptosis (PMID: 39096699, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06525298 | Phase Ib/II | Darolutamide + EIS-12656 EIS-12656 EIS-12656 + Trastuzumab deruxtecan | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | Recruiting | USA | 0 |